|(S)-N-((S)-5-氨基-1-((2-氨基-2-氧代乙基)氨基)-1-氧代戊烷-2-基)-1-((4R,7S,10S,13S,16R)-7-(2-氨基-2-氧代乙基)-13-((S)-仲丁基)-16-(4-乙氧基苄基)-10-((R)-1-羟乙基)-6,9,12,15,18-五氧代-1,2-二硫代-5,8,11,14,17-五氮杂环二十烷-4-羰基)吡咯烷-2-甲酰胺|CsnPharm

CAS No.: 90779-69-4

阿托西班 Catalog No. CSN10352

Synonyms: RW22164;RWJ22164;Antocin

Atosiban is competitive antagonist of vasopressin and oxytocin receptors. It is a nonapeptide and the analogue of desamino-oxytocin.

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

描述Atosiban is a nonapeptide competitive vasopressin/oxytocin receptor antagonist, and is a desamino-oxytocin analogue. Atosiban inhibits the oxytocin-mediated release of IP3 from the myometrial cell membrane. There is reduced release of intracellular, stored calcium from the sacroplasmic reticulum of myometrial cells, and reduced influx of Ca2+ from the extracellular space through voltage gated channels. In addition, Atosiban suppresses oxytocin-mediated release of PGE and PGF from the decidua^[3]. Atosiban resulted in fewer maternal side-effects than nifedipine, with no difference in pregnancy prolongation^[4].
临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT00599898	Labor, Premature	Phase 4	Completed	-	Israel ... more >> HaEmek Medical Center Afula, Israel, 18100 Collapse <<
NCT01796522	Preterm Delivery.	Phase 3	Withdrawn(have been published ... more >>new studies that it showed the ineffectiveness of the treatments proposed in this study.) Collapse <<	May 2013	Spain ... more >> Hospital Universitari y Politécnic La Fe Valencia, Spain, 46026 Collapse <<
NCT02292784	Obstetric Labour, Premature	Phase 2 Phase 3	Recruiting	July 29, 2022	-

更多
参考文献

[1] Sanu O, Lamont RF. Critical appraisal and clinical utility of atosiban in the management of preterm labor. Ther Clin Risk Manag. 2010 Apr 26;6:191-9.
[2] Akerlund M, Carlsson AM, et al. The effect on the human uterus of two newly developed competitive inhibitors of oxytocin and vasopressin. Acta Obstet Gynecol Scand. 1985;64(6):499-504.
[3] Sanu O, Lamont RF. Critical appraisal and clinical utility of atosiban in the management of preterm labor. Ther Clin Risk Manag. 2010 Apr 26;6:191-9
[4] Ali AA, Sayed AK, El Sherif L, Loutfi GO, Ahmed AMM, Mohamed HB, Anwar AT, Taha AS, Yahia RM, Elgebaly A, Abdel-Daim MM. Systematic review and meta-analysis of randomized controlled trials of atosiban versus nifedipine for inhibition of preterm labor. Int J Gynaecol Obstet. 2019 May;145(2):139-148

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 1.0058 mL
- 5.0292 mL
- 10.0585 mL
- 5 mM
- 0.2012 mL
- 1.0058 mL
- 2.0117 mL
- 10 mM
- 0.1006 mL
- 0.5029 mL
- 1.0058 mL

技术信息

CAS号

90779-69-4

储存条件

粉末: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C

液体: -20°C:3-6 月 -80°C:12月

分子式

C43H67N11O12S2

运输

蓝冰

分子量

994.19

别名

RW22164;RWJ22164;Antocin;ORF 22164;Tractocile;阿托西班

溶解度

DMSO	300.0 mg/mL (301.8 mM)
Water	125.0 mg/mL (125.7 mM)

动物实验配方

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT00599898	Labor, Premature	Phase 4	Completed	-	Israel ... more >> HaEmek Medical Center Afula, Israel, 18100 Collapse <<
NCT01796522	Preterm Delivery.	Phase 3	Withdrawn(have been published ... more >>new studies that it showed the ineffectiveness of the treatments proposed in this study.) Collapse <<	May 2013	Spain ... more >> Hospital Universitari y Politécnic La Fe Valencia, Spain, 46026 Collapse <<
NCT02292784	Obstetric Labour, Premature	Phase 2 Phase 3	Recruiting	July 29, 2022	-
NCT00587327	In Vitro Fertilisation (IVF) T... more >>reatment Collapse <<	Phase 2	Completed	-	Belgium ... more >> UZ Brussel, Center for Reproductive Medicine Brussels, Belgium Czechia Institute for Reproductive Medicine and Endocrinology Pilsen, Czechia, 30177 ISCARE IVF a.s. Prague, Czechia Spain Institut Universitari Dexeus Barcelona, Spain, 08028 IVI Madrid Madrid, Spain, 28035 Collapse <<
NCT02725736	Labor Preterm Multiple	Phase 3	Unknown	March 2018	-
NCT01673399	Implantation Failure	Phase 4	Recruiting	-	Belgium ... more >> AZ Jan Palfijn Recruiting Gent, Oost-vlaanderen, Belgium, 9000 Contact: Wim Decleer, gynecologist 0032 9 2243024 wim.decleer@janpalfijngent.be Contact 0032 9 2248851 ivf.studie@janpalfijngent.be Principal Investigator: Wim Decleer, gynecologist Collapse <<
NCT03369262	Preterm Labor	Phase 2	Recruiting	September 2021	Finland ... more >> Helsinki Universisty Hospital Recruiting Helsinki, Finland Contact: Investigator, MD Spain Hospital La Paz Not yet recruiting Madrid, Spain Contact: Investigator, MD Collapse <<
NCT01429545	Preterm Labour	Phase 2	Completed	-	United Arab Emirates ... more >> Department of obstetrics and Gynecology, Tawam Hospital Al Ain, Abudhabi, United Arab Emirates, 15258 Tawam Hospital Al Ain, Abudhabi, United Arab Emirates, 15258 Collapse <<
NCT00679705	Healthy	Phase 1	Completed	-	Belgium ... more >> University Hospital Ghent Ghent, Belgium, 9000 Collapse <<
NCT01314859	Threatened Preterm Labor	Phase 3	Withdrawn	July 2013	-
NCT02292771	Obstetric Labour, Premature	Phase 3	Terminated(The study was stopp... more >>ed due to the feasibility of recruiting the study in a timely manner) Collapse <<	-	-
NCT02292771	-	-	Terminated(The study was stopp... more >>ed due to the feasibility of recruiting the study in a timely manner) Collapse <<	-	-
NCT01493440	Repeated Implantation Failure	Not Applicable	Completed	-	Vietnam ... more >> IVFAS, An Sinh Hospital Ho Chi Minh City, Ho Chi Minh, Vietnam, 8 Collapse <<
NCT02893722	Repeated Implantation Failure	Phase 1	Unknown	December 2018	-
NCT03570294	Premature Birth	Not Applicable	Active, not recruiting	December 30, 2018	Poland ... more >> Department of Obstetrics, Perinatology and Gynecology, Polish Mother's Memorial Hospital-Research Institute Łódź, Poland, 93-338 Collapse <<
NCT01501214	Subfertility	Phase 4	Completed	-	China, Guangdong ... more >> Reproductive Medical Center of Nanfang Hospital Guangzhou, Guangdong, China, 510515 Vietnam CGRH, School of Medicine Ho Chi Minh City, Vietnam Collapse <<

阿托西班 Catalog No. CSN10352

靶点选择性

请登录您的专属账户

确认信息